Persantin—a Double Blind Study

Abstract

Double blind evaluation of hospitalized decompensated cardiac patients indicates that definite improvement may result from the administration of Persantin (dysyridomole). Digitalis toxicity does not appear to contraindicate the use of Persantin. Anginal symptoms in patients with clinical coronary disease may be alleviated when Persantin is given for periods of several months. It is postulated that Persantin may act by a metabolic mechanism favorably influencing the depleted stores of adenosine triphosphate in the decompensated myocardium, in addition to its coronary vasodilating effect.